Navigation Links
Predicting the age at menopause of women having suffered from childhood cancers
Date:12/4/2012

This press release is available in French.

This study provided important data about the fertility window of women who had suffered from childhood cancer and information concerning the associated risk factors, but did not confirm the greater risk of premature menopause (before the age of 40) that was reported by the American studies.

The results were published in the review Human Reproduction of November 15.

Women who have suffered from childhood cancer are known to run a greater risk of premature menopause. However, data about the associated risk factors is limited. Researchers from unit 1018 "Centre for Research in Epidemiology and Population Health (CESP)" (Inserm/Universit Paris-Sud/Institut Gustave Roussy) and from the AP-HP analyzed the data from a French cohort, named Euro2k, concerning 1522 survivors of childhood cancer diagnosed between 1945 and 1986 when they were under 18, initially in order to study the mortality rate. The study estimated the radiation doses received at the ovaries by the women in this cohort who had been treated by radiotherapy. 706 of these women filled in a detailed questionnaire about their state of health. 32% of these women had already reached the age of 40 years; 7% were over 50 years of age. The research team studied the age at menopause of these women and the potentially associated risk factors. The researchers based this study on self-reported questionnaires sent to the women in order to obtain information about the menopause, without confirming by measuring FSH levels.

Analysis of this data showed that 97 women (13,7%) were menopaused at a median age of 44 years, in other words, 7 years earlier than the general population. For a third of these women (36%), menopause was surgically induced.

The researchers concentrated on the risk factors of menopause in these women, who had been subjected to various cancer treatments during childhood. It appeared that being treated during puberty was associated with a risk of non-surgical menopause. At a given age, the maximum risk of early menopause was observed in women who had been treated after the onset of puberty with alkylating agents (either alone or along with even a minimum dose of radiation to the ovaries, for example 0.01 Gray). Menopause occurred on average 4 years earlier in women who had been exposed to these agents. Having undergone unilateral oophorectomy is also associated with a 7-year earlier age at menopause.

The results showed that women who had suffered from a childhood cancer were more likely to suffer from early menopause, but did not conform the high risk of premature menopause (in other words, before 40 years of age), such as was reported in the American studies. This is probably due to the difference between the populations studied (there were no cases of leukemia or lymphoma in the Euro2k cohort population).

"In this cohort , very few women had received high doses of radiotherapy in order to receive bone marrow transplants, and only 21% of them (i.e. twice the occurrence of the general population) suffered premature menopause before the age of 40″, explained Ccile Teinturier, the principal writer of the study. The main risk factors associated to these cases of premature menopause are: the older the women is when being treated for cancer, the dose of alkyating agents such as Cyclophosphamide or Melphalan received during bone marrow transplants, and the radiation dose received at the ovaries.

"This study provided information about the risk factors affecting the fertility window of women who have suffered from childhood cancer. This new data should help both to inform patients who are at risk of premature menopause, by advising them not to delay their first pregnancy until after the age of thirty, and to reassure women who present a low risk" concluded Ccile Teinturier.

It is planned to extend Cohort Euro2k to cover all patients treated for solid cancers who were under 18 years of age before the year 2000 inFrance. The aim is to study the impact of high-dose chemotherapy on the occurrence of premature menopause.


'/>"/>
Contact: Inserm press office
presse@inserm.fr
INSERM (Institut national de la sant et de la recherche mdicale)
Source:Eurekalert

Related biology news :

1. Disease-carrying colonizers on the move: Predicting the spread of ticks across Canada
2. Researchers identified a protein useful in predicting the risk of pulmonary metastases in breast cancer patients
3. Discovery of mechanisms predicting response to new treatments in colon cancer
4. Predicting how patients respond to therapy
5. New model could help fill data gap in predicting historical air pollution exposure
6. Cellular landscaping: Predicting how, and how fast, cells will change
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Menopause evolved to prevent competition between in-laws
9. Is long-term weight loss possible after menopause?
10. Early menopause: A genetic mouse model of human primary ovarian insufficiency
11. Long menopause allows killer whales to care for adult sons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2016)... Minn. , Nov. 22, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... Medical LiveWire Healthcare and Life Sciences Awards ... award caps off an unprecedented year of recognition and ... trials for over 15 years. iMedNet ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is ... analysis for Private Biobanks shows the highest Compounded Annual Growth ... region during the analysis period 2014-2020. ... CAGR of 9.95% followed by Europe ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
Breaking Biology News(10 mins):
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... ) today announced the submission of a Marketing Authorization Application ... a biosimilar candidate to Avastin ® (bevacizumab). The companies ... to the EMA. "The submission of ABP ... seeks to expand our oncology portfolio," said Sean E. ...
(Date:12/2/2016)... ... , ... ACEA Biosciences, Inc. announced today that it will be presenting updated ... World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR T790M ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... (CSS) and the popularity of US Single Day Events (SDE) to organize a ... Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life sciences industry ...
(Date:12/2/2016)... IL (PRWEB) , ... December 01, 2016 , ... ... to congratulate long-term client Nanowear on their recent FDA Class II 510(k) clearance ... cleared a significant hurdle in commercializing remote cardiac monitoring devices that rely on ...
Breaking Biology Technology: